"Gliosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Rare mixed tumors of the brain and rarely the spinal cord which contain malignant neuroectodermal (glial) and mesenchymal components, including spindle-shaped fibrosarcoma cells. These tumors are highly aggressive and present primarily in adults as rapidly expanding mass lesions. They may arise in tissue that has been previously irradiated. (From Br J Neurosurg 1995 Apr;9(2):171-8)
| Descriptor ID |
D018316
|
| MeSH Number(s) |
C04.557.465.625.600.380.400 C04.557.470.670.380.400 C04.557.580.625.600.380.400
|
| Concept/Terms |
Gliosarcoma- Gliosarcoma
- Gliosarcomas
- Glioblastoma with Sarcomatous Component
- Sarcomatous Glioma
- Glioma, Sarcomatous
- Gliomas, Sarcomatous
- Sarcomatous Gliomas
|
Below are MeSH descriptors whose meaning is more general than "Gliosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Gliosarcoma".
This graph shows the total number of publications written about "Gliosarcoma" by people in this website by year, and whether "Gliosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gliosarcoma" by people in Profiles.
-
Primary versus secondary gliosarcoma: a systematic review and meta-analysis. J Neurooncol. 2022 Aug; 159(1):195-200.
-
Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Sci Rep. 2021 09 09; 11(1):18009.
-
Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. BMC Neurol. 2021 Jun 23; 21(1):231.
-
NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. Cancer. 2020 06 15; 126(12):2821-2828.